And yet, somehow, US pharma companies are overcharging diabetics to the tune of thousands of dollars a year for access to a 96-year-old drug.
I'm sure those same pharma companies can figure out how to fleece the public in the distribution of any cancer cures that come out of China.
And yet, somehow, US pharma companies are overcharging diabetics to the tune of thousands of dollars a year for access to a 96-year-old drug.
I'm sure those same pharma companies can figure out how to fleece the public in the distribution of any cancer cures that come out of China.